Priothera Reports the First Patients Enrollment of Mocravimod in P-IIb/III Trial (MO-TRANS) for the Treatment of Acute Myeloid Leukemia
Shots:
- The first patients have been enrolled in the P-IIb/III trial (MO-TRANS) evaluating mocravimod as an adjunctive & maintenance therapy in AML patients undergoing allogeneic HCT. The trial initiates in the EU, Israel, the US & in additional Asian & Latin American countries
- The study will be based on the pre-clinical & clinical PoC studies which showed the ability of mocravimod to improve survival outcomes for hematological malignancies requiring allogeneic HCT. The P-IIb/III trial will evaluate relapse-free & overall survival of 2 dose levels of mocravimod over PBO, results are expected in 2025
- In the P-Ib/IIa study, mocravimod was safe & well tolerated. Mocravimod, a sphingosine 1 phosphate receptor modulator showed a benefit in an early clinical study
Ref: PRNewswire | Image: Priothera
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
